WATCH | Goal is to get price as low as possible, says HIV jab producer as Sahpra registers drug

05 December 2022 - 15:21 By Mia Malan and Mohale Moloi
subscribe Just R20 for the first month. Support independent journalism by subscribing to our digital news package.
Subscribe now

South Africa’s medicine regulator, Sahpra, has registered CAB-LA, a new anti-HIV jab. But for how much will drugmaker ViiV Healthcare sell it to the government? The Bhekisisa Centre for Health Journalism asked them in their TV programme Health Beat

Bhekisisa editor-in-chief Mia Malan spoke to Dr Kimberly Smith, head of research and development at ViiV Healthcare, about the drug's pricing, clinical trials and availability.

This story was produced by the Bhekisisa Centre for Health Journalism. Sign up for the newsletter.


subscribe Just R20 for the first month. Support independent journalism by subscribing to our digital news package.
Subscribe now

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.